1388. Dose Discrimination for ASN100: Bridging from Rabbit Survival Data to Predicted Activity in Humans Using a Minimal Physiologically Based Pharmacokinetic (mPBPK) Model

BACKGROUND: ASN100 is a combination of two co-administered fully human monoclonal antibodies (mAbs), ASN-1 and ASN-2, that together neutralize the six cytotoxins critical to S. aureus pneumonia pathogenesis. ASN100 is in development for prevention of S. aureus pneumonia in mechanically ventilated pa...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Open Forum Infect Dis
मुख्य लेखकों: Rubino, Christopher M, Stulik, Lukas, Rouha, Harald, Visram, Zehra, Badarau, Adriana, Wart, Scott A Van, Ambrose, Paul G, Goodwin, Matthew M, Nagy, Eszter
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Oxford University Press 2018
विषय:
Abstracts
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6252729/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy210.1219
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन